Mirae Asset Global Investments Co. Ltd. Purchases New Shares in Becton, Dickinson and Company $BDX

Mirae Asset Global Investments Co. Ltd. bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the third quarter, Holdings Channel reports. The institutional investor bought 80,548 shares of the medical instruments supplier’s stock, valued at approximately $14,418,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Brown Lisle Cummings Inc. grew its position in Becton, Dickinson and Company by 9.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock worth $97,000 after purchasing an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. increased its stake in Becton, Dickinson and Company by 12.3% in the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock valued at $94,000 after purchasing an additional 56 shares during the period. Elevation Point Wealth Partners LLC raised its holdings in shares of Becton, Dickinson and Company by 3.7% in the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 60 shares during the last quarter. Private Harbour Investment Management & Counsel LLC raised its holdings in shares of Becton, Dickinson and Company by 1.1% in the second quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after buying an additional 62 shares during the last quarter. Finally, Trifecta Capital Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 59.0% in the third quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.4%

BDX opened at $197.88 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $200.47. The stock has a market capitalization of $54.52 billion, a P/E ratio of 59.60, a P/E/G ratio of 13.39 and a beta of 0.22. The business has a 50 day simple moving average of $186.86 and a 200-day simple moving average of $170.20.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on BDX shares. Weiss Ratings raised Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. Zacks Research upgraded Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Piper Sandler upped their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Finally, TD Cowen lifted their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $185.07.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,907 shares of company stock worth $1,269,128 over the last 90 days. Company insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.